Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors

被引:35
|
作者
Rocha, Debora A. [1 ,2 ]
Silva, Elany B. [3 ]
Fortes, Isadora S. [1 ]
Lopes, Marcela S. [4 ]
Ferreira, Rafaela S. [3 ]
Andrade, Saulo F. [1 ,2 ]
机构
[1] Univ Fed Rio Grande do Sul, Pharmaceut Synth Grp PHARSG, Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS, Brazil
[3] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil
[4] Univ Fed Rio Grande do Sul, Dept Prod Mat Prima, Porto Alegre, RS, Brazil
关键词
Chagas disease; Human african trypanosomiasis; Cruzain; Rhodesain; Inhibitors; Synthesis; CYSTEINE PROTEASE INHIBITORS; TRYPANOSOMA-CRUZI; BIOLOGICAL EVALUATION; CHAGAS-DISEASE; TARGET VALIDATION; CRYSTAL-STRUCTURE; VINYL SULFONES; P-GLYCOPROTEIN; POTENT; DESIGN;
D O I
10.1016/j.ejmech.2018.08.079
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chagas disease and Human African trypanosomiasis (HAT) are important public health issues in Latin American and sub-Saharan African countries, respectively, and are responsible fora significant number of deaths. The drugs currently used to treat Chagas disease and HAT present efficacy, toxicity, and/or resistance issues; thus, there is a clear need for the discovery of novel targets and drug candidates to combat these diseases. In recent years, much effort has been made to find inhibitors of cruzain and rhodesain, which are promising targets for the design of novel trypanocidal compounds, since they are essential for parasite survival. Many reviews covering the design of novel cruzain and rhodesain inhibitors have been published; however, none have focused on the chemistry of the inhibitors. Thus, in the present work we reviewed the synthetic strategies and routes for the preparation of relevant classes of cruzain and rhodesain inhibitors. Perhaps the most important are the vinyl sulfone derivatives, and a very efficient synthetic strategy based on the Horner-Wadsworth-Emmons reaction was developed to yield these compounds. Modern approaches such as the asymmetric addition of substituted ethynyllithium to N-sulfinyl ketimines were used to produce the chiral alkynes that were employed in the preparation of important chiral triazole derivatives (potent cruzain inhibitors) and chiral HPLC resolution was used for the preparation of enantiopure 3-bromoisoxazoline derivatives (rhodesain inhibitors). Moreover, we also highlight the most important activity results and updated SAR results. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1426 / 1459
页数:34
相关论文
共 50 条
  • [21] Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors
    Sonawane, Yogesh A.
    Zhu, Yingmin
    Garrison, Jered C.
    Ezell, Edward L.
    Zahid, Muhammad
    Cheng, Xiaodong
    Natarajan, Amarnath
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (11): : 1183 - 1187
  • [22] Structure-activity relationship studies of SETD8 inhibitors
    Ma, Anqi
    Yu, Wenyu
    Xiong, Yan
    Butler, Kyle V.
    Brown, Peter J.
    Jin, Jian
    MEDCHEMCOMM, 2014, 5 (12) : 1892 - 1898
  • [23] Quantitative structure-activity relationship studies of mushroom tyrosinase inhibitors
    Xue, Chao-Bin
    Luo, Wan-Chun
    Ding, Qi
    Liu, Shou-Zhu
    Gao, Xing-Xiang
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2008, 22 (05) : 299 - 309
  • [24] Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies
    de Souza, Anacleto S.
    de Oliveira, Marcelo T.
    Andricopulo, Adriano D.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2017, 31 (09) : 801 - 816
  • [25] Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors
    Pauli, Ivani
    Ferreira, Leonardo G.
    de Souza, Mariana L.
    Oliva, Glaucius
    Ferreira, Rafaela S.
    Dessoy, Marco A.
    Slafer, Brian W.
    Dias, Luiz C.
    Andricopulo, Adriano D.
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (07) : 641 - 657
  • [26] Synthesis and structure-activity relationship of inhibitors of protein kinase D
    Rosenker, Kara M. George
    Bravo-Altamirano, Karla
    Frantz, Marie-Celine
    LaValle, Courtney R.
    Tandon, Manuj
    Wang, Q. Jane
    Wipf, Peter
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [27] The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors
    Ting, Pauline C.
    Kuang, Rongze
    Wu, Heping
    Aslanian, Robert G.
    Cao, Jianhua
    Kim, David W.
    Lee, Joe F.
    Schwerdt, John
    Zhou, Gang
    Wainhaus, Samuel
    Black, Todd A.
    Cacciapuoti, Anthony
    McNicholas, Paul M.
    Xu, Yiming
    Walker, Scott S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) : 1819 - 1822
  • [28] Synthesis and structure-activity relationship studies of teixobactin analogues
    Wu, Chunlei
    Pan, Zhengyin
    Yao, Guiyang
    Wang, Wei
    Fang, Lijing
    Su, Wu
    RSC ADVANCES, 2017, 7 (04): : 1923 - 1926
  • [29] Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification
    Pinto Braga, Saulo Fehelberg
    Martins, Luan Carvalho
    da Silva, Elany Barbosa
    Sales Junior, Policarpo Ademar
    Fonseca Murta, Silvane Maria
    Romanha, Alvaro Jose
    Soh, Wai Tuck
    Brandstetter, Hans
    Ferreira, Rafaela Salgado
    de Oliveira, Renata Barbosa
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (06) : 1889 - 1900
  • [30] Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement
    Gomes, Juliana C.
    Cianni, Lorenzo
    Ribeiro, Jean
    Rocho, Fernanda dos Reis
    Martins Silva, Samelyn da Costa
    Jatai Batista, Pedro Henrique
    Moraes, Carolina Borsoi
    Franco, Caio Haddad
    Freitas-Junior, Lucio H. G.
    Kenny, Peter W.
    Leitao, Andrei
    Burtoloso, Antonio C. B.
    de Vita, Daniela
    Montanari, Carlos A.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (22)